tbuckley/cabot-search huggingface dataset:
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
Authors: Cheng Zhou, Xiumin Yang, Bin Yang, Guofu Yan, Xiuqin Dong, Yangfeng Ding, Weixin Fan, Linfeng Li, Dingquan Yang, Hong Fang, Chao Ji, Hao Cheng, Shoumin Zhang, Aik Han Goh, Rongjun Liu, Xiaoyu Gu, Zaili Weng, Peter Foley, Rodney Sinclair, Jianzhong Zhang
Journal: Journal of the American Academy of Dermatology (2023)
80TiP High-dose aumolertinib versus osimertinib in EGFR T790M+ NSCLC patients with brain metastases (ATTACK)
Authors: S. Lu, L. Han, D. Lv, Z. Zhang, J. Wu, Q. Wang, X. Dong, Y. Hu, J. Chen, L. Wu
Journal: Journal of Thoracic Oncology (2023)
190P EORTC-SPECTA Arcagen project: Results of the prospective rare thoracic tumors cohort
Authors: M. Tagliamento, M. Morfouace, C. Loizides, J. Oliveira, L. Greiller, J. Raimbourg, A.C. Toffart, T. Chatelier, N. Cloarec, I.G. Sullivan, B. Brasiuniene, J. Peron, K. Oselin, M-S. Robert, C. Fernandes, A. Poncin, J-Y. Blay, B. Besse, N. Girard
Journal: Journal of Thoracic Oncology (2023)
Issue Information
Journal: Medicinal Research Reviews (2023)

Aims and Scope:The journal publishes timely critical reviews of topics related to medicinal research, broadly defined, to which the authors have made significant contributions.Appropriate topics include, but are not limited to, the underlying pathophysiology of important diseases and disease vectors; therapeutic approaches to the treatment of various diseases; the properties of molecular targets for therapeutic agents; important new methodologies facilitating the search for therapies; genomics and proteomics; structure-activity correlations of drug series; the development of new imaging and diagnostic tools; drug metabolism; drug delivery; and chemical, pharmacological, pharmacokinetic, pharmacodynamic, and clinical characteristics of important drugs.Articles are mainly solicited by the editors; however, voluntary contributions are also encouraged.In the latter case, potential authors are asked to contact the Editor-in-Chief with an outline before beginning to write in order to avoid duplication of effort and to ensure suitability of the topic and the level of coverage.
89P A clinical- and biological-based nomogram to predict unforeseen nodal metastases in clinically node-negative, radically resected lung adenocarcinoma
Authors: F.T. Gallina, F.L. Cecere, R. Tajè, D. Forcella, L. Landi, G. Minuti, S. Buglioni, P. Visca, E. Melis, I. Sperduti, F. Cappuzzo, F. Facciolo
Journal: Journal of Thoracic Oncology (2023)
172P A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer
Authors: J. Peng, R. Meng, X. Liu, L. Zhang, L. Wang, R. Feng, H. Feng, Z. Huang, D. Yao, X. Li, N. Liu, B. Tan, S. Li, J. Yu, X. Meng
Journal: Journal of Thoracic Oncology (2023)
58P Treatment combinations in non-driver mutated mNSCLC: A systematic review and Bayesian network meta-analysis
Authors: P. Umesh, K.S. Chufal, I. Ahmad, R. Bajpai, A.A. Miller, R. Chowdhary, M.I. Sharief, A. Dekker, L. Wee, A.M. Ansari, M. Gairola
Journal: Journal of Thoracic Oncology (2023)
Antibiotic-based small molecular micelles combined with photodynamic therapy for bacterial infections
Authors: Lijiao Yang, Shaomin Song, Meihui Yin, Min Yang, Daoping Yan, Xiaohui Wan, Jipeng Xiao, Yuchen Jiang, Yongchao Yao, Jianbin Luo
Journal: Asian Journal of Pharmaceutical Sciences (2023)

The appearance of multidrug-resistant bacteria and the formation of bacterial biofilms have necessitated the development of alternative antimicrobial therapeutics. Antibiotics conjugated with or embedded in nano-drug carriers show a great potential and advantage over free drugs, but the mass proportion of carriers generally exceeds 90% of the nano-drug, resulting in low drug loading and limited therapeutic output. Herein, we fabricated a nanocarrier using antibiotics as the building blocks, minimizing the use of carrier materials, significantly increasing the drug loading content and treatment effect. Firstly, we conjugated betaine carboxylate with ciprofloxacin (CIP) through an ester bond to form the amphiphilic conjugate (CIP-CB), which self-assembled into micelles (CIP-CBMs) in aqueous solutions, with a CIP loading content as high as 65.4% and pH-induced surface charge reversal properties. Secondly, a model photosensitizer (5, 10, 15, 20-tetraphenylporphyrin (TPP)) was encapsulated in CIP-CBMs, generating infection-targeted photodynamic/antibiotic combined nanomedicines (denoted as TPP@CIP-CBMs). Upon accumulation at infection sites or in deep bacterial biofilms, the ester bond between the betaine carboxylate and CIP is cleaved to release free TPP and CIP, leading to a synergetic antibacterial and antibiofilm activity in vitro and in vivo.
188P SAKK 16/14: Immune profiling of pre-operative biopsies correlates with survival and immune activation in stage IIIA (N2) NSCLC after neoadjuvant immunotherapy
Authors: S.I. Rothschild, A.B. Sobottka-Brillout, G. Tochtermann, M. Trueb, M. Nowak, I. Alborelli, K. Leonards, M. Manzo, E.B. Keller, P. Herzig, D. Schmid, S. Hayoz, S. Chiquet, M. Schneider, M. Pless, P. Jermann, A. Zippelius, S. Savic Prince, V.H. Koelzer
Journal: Journal of Thoracic Oncology (2023)
166P Investigating the correlation between circulating tumor cell (CTC) detection and immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Authors: S. Agelaki, A. Boumpouli, N. Nikolarakou, E. Vorrias, K. Michaelidou, A. Mala, A.C. Kyriakidou, D. Mavroudis, M.A. Papadaki
Journal: Journal of Thoracic Oncology (2023)
Sensitivity optimization of a rhodopsin-based fluorescent voltage indicator
Authors: Ahmed S. Abdelfattah, Jihong Zheng, Amrita Singh, Yi-Chieh Huang, Daniel Reep, Getahun Tsegaye, Arthur Tsang, Benjamin J. Arthur, Monika Rehorova, Carl V.L. Olson, Yichun Shuai, Lixia Zhang, Tian-Ming Fu, Daniel E. Milkie, Maria V. Moya, Timothy D. Weber, Andrew L. Lemire, Christopher A. Baker, Natalie Falco, Qinsi Zheng, Jonathan B. Grimm, Mighten C. Yip, Deepika Walpita, Martin Chase, Luke Campagnola, Gabe J. Murphy, Allan M. Wong, Craig R. Forest, Jerome Mertz, Michael N. Economo, Glenn C. Turner, Minoru Koyama, Bei-Jung Lin, Eric Betzig, Ondrej Novak, Luke D. Lavis, Karel Svoboda, Wyatt Korff, Tsai-Wen Chen, Eric R. Schreiter, Jeremy P. Hasseman, Ilya Kolb
Journal: Neuron (2023)
75TiP A multicenter, open-label, phase II trial evaluating the safety and efficacy of folate receptor alpha (FRα) antibody-drug conjugate (ADC) farletuzumab ecteribulin (FZEC*) in patients with previously treated, metastatic non-small cell lung cancer (NSCLC) adenocarcinoma (AC)
Authors: D. Planchard, L. Paz-Ares, A. Spira, E. Felip, S. McCune, T. Cascella, J. Dennie, P. Bhagavatheeswaran, C. Dumitru, H. Borghaei
Journal: Journal of Thoracic Oncology (2023)
76TiP Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in metastatic lung cancer
Authors: I. Massalha, A. Segal, M.T. Moskovitz, A. Yakobson, R. Zabit, S.M. Stemmer, W. Shalata, Y. Dudnik, G. Markel, N. Geva-Zatorsky, A. Meirovitz
Journal: Journal of Thoracic Oncology (2023)
131TiP A phase I–III platform study evaluating the safety and efficacy of multiple therapies in patients (pts) with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)
Authors: L. Paz-Ares, C.M. Gay, C. Zhou, T. Kato, L. Corrales, K. Redhead, A. Rahman, D. Bradley, E. Theogaraj, K.E. Hutchinson, S.M. Shagan, B.J. Solomon
Journal: Journal of Thoracic Oncology (2023)
78TiP Phase Ib/IIa safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations
Authors: R. Veluswamy, S. Bhalla, R. Mehra, O. Gligich, M.C. Garassino, C. Oliva, C. Gorcea-Carson, N. McCracken
Journal: Journal of Thoracic Oncology (2023)
49P Patient-reported outcomes (PROs) in patients with advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% receiving cemiplimab (CEMI) monotherapy vs chemotherapy (CHEMO): EMPOWER-Lung 1 liver metastases subpopulation
Authors: A. Baramidze, C. Gessner, M. Gogishvili, A. Sezer, T. Makharadze, S. Kilickap, M. Gumus, X. He, G. Gullo, P. Rietschel, R. Quek
Journal: Journal of Thoracic Oncology (2023)
38P Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)
Authors: M.J. Hochmair, E. Nadal, Y. D’yachkova, T. Puri, A. Vickers, S. Wolowacz, X. Wang, U. Kiiskinen
Journal: Journal of Thoracic Oncology (2023)
207P Does age affect PD-L1 expression? Results of a single-center analysis of a large cohort of patients
Authors: M. Knetki-Wroblewska, P. Wiśniewski, A. Szatkowska-Tomczyk, J. Owczarek, M. Krzakowski, M. Prochorec-Sobieszek
Journal: Journal of Thoracic Oncology (2023)
98P Adjuvant aumolertinib in resected EGFR-mutated non-small cell lung cancer: A multiple-center real-world experience
Authors: Q. Zhang, L. Ke, S. Huang, Y. Yang, T. He, H. Sun, Z. Wu, X. Zhang, H. Zhang, W. Lv, J. Hu
Journal: Journal of Thoracic Oncology (2023)
107P Artificial intelligence-based volumetric classification of pulmonary nodules in Chinese baseline lung cancer screening population (NELCIN-B3)
Authors: Y. Mao, H.L. Lancaster, B. Jiang, D. Han, M. Vonder, M.D. Dorrius, D. Yu, J. Yi, G.H. de Bock, M. Oudkerk
Journal: Journal of Thoracic Oncology (2023)
45P DCVAC/LuCa with chemotherapy in patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations: Five-year survival update
Authors: X. Ling, R. Zhong, S. Cao, L. Zhang, J. Xu, B. Zhang, X. Zhang, H. Wang, B. Han, H. Zhong
Journal: Journal of Thoracic Oncology (2023)
168P Demographics, clinical characteristics, treatment (tx) patterns and clinical outcomes for patients (pts) with limited-stage SCLC (LS-SCLC)
Authors: A.C. Chiang, R.J-B. Salomonsen, A. Wang, R. Holland, L. Cai, Y. Xiao, S. Sadow, K. Davey, P. Iyengar
Journal: Journal of Thoracic Oncology (2023)
68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC
Authors: P. Ambrosini, L. Provenzano, A. Bottiglieri, A. Spagnoletti, G. Di Guida, L. Mazzeo, T. Beninato, R. Leporati, M. Occhipinti, M. Brambilla, S. Manglaviti, M. Ganzinelli, V. Miskovic, C. Proto, A.D. Dumitrascu, F.G.M. De Braud, C.M. Della Corte, G. Lo Russo, G. Viscardi, A. Prelaj
Journal: Journal of Thoracic Oncology (2023)
34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
Authors: F. Griesinger, M.C. Garassino, E. Felip, H. Sakai, X. Le, R. Veillon, E.F. Smit, J. Raskin, M. Thomas, M-J. Ahn, S. Vlassak, R. Bruns, A. Johne, P.K. Paik
Journal: Journal of Thoracic Oncology (2023)
19P Mortality among EGFR-mutated advanced NSCLC patients after frontline osimertinib treatment: A real-world, US attrition analysis
Authors: N. Girard, N. Leighl, Y. Ohe, T.M. Kim, L. Demirdjian, A.B. Bourla, A. Abdul Sultan, P. Mahadevia, J.M. Bauml, J. Sabari
Journal: Journal of Thoracic Oncology (2023)
173P Extended-stage SCLC (ES-SCLC) patients treated with first-line chemotherapy plus atezolizumab in Spain: Characteristics and outcomes
Authors: P. Gómez-Mugarza, S. Laguna, M. Zapata, L. Fernandez Prado, J. Gimeno, A. Nuño, N. Galan, I. Gil Arnaiz, A. Artal-Cortes
Journal: Journal of Thoracic Oncology (2023)
40 Patient-reported outcomes from the CodeBreaK 200 phase III trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC
Authors: D.M. Waterhouse, S. Rothschild, C. Dooms, B. Mennecier, F. Bozorgmehr, M. Majem, M. van den Heuvel, H. Linardou, B. Chul-Cho, R. Roberts-Thomson, I. Okamoto, N. Blais, G. Schvartsman, K. Holmskov, I. Chmielewska, M. Forster, B. Stollenwerk, C.C. Obiozor, Y. Wang, S. Novello
Journal: Journal of Thoracic Oncology (2023)
46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study
Authors: R. Matsuzawa, M. Morise, K. Ito, O. Hataji, K. Takahashi, Y. Kuwatsuka, Y. Goto, K. Imaizumi, H. Itani, T. Yamaguchi, Y. Zenke, M. Oki, M. Ishii
Journal: Journal of Thoracic Oncology (2023)
44P Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial
Authors: A.L.O. Ortega Granados, S.M. Lim, M. Schenker, F. de Marinis, J.M. Puig, D.H. Lee, E. Arriola, J. Fuentes Pradera, S. O’Donnell, Z. Szijgyarto, L. Cho, J.S. Ahn
Journal: Journal of Thoracic Oncology (2023)
150P Sex differences in inoperable lung cancer risk and prognosis: Evidence from low-income population setting
Authors: M.R. Islam, G. Rabbani, S.M. Siddiqua, S.M.A. Islam, R. Islam, A. Hossain, N. Hossen, B. Saha, N. Khatun, S.M. Alif, M.N. Karim
Journal: Journal of Thoracic Oncology (2023)
127P Stereotactic ablative radiotherapy and durvalumab: The backbone of unresectable locally advanced non-small cell lung cancer patients unfit to concurrent chemo-radiotherapy -Rib of START-NEW-ERA trial
Authors: F. Arcidiacono, F. Trippa, E. Maranzano, M. Italiani, M. Casale, P. Anselmo
Journal: Journal of Thoracic Oncology (2023)
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Authors: P.A. Jänne, A. Spira, G.J. Riely, S. Gadgeel, R. Heist, S-H.I. Ou, M.L. Johnson, J. Sabari, K. Velastegui, J.G. Christensen, W. Yang, K. Anderes, R. Chao, C. Paweletz
Journal: Journal of Thoracic Oncology (2023)
28P Generation and validation of a predictive model using pretreatment clinical factors for estimating survival and T790M mutation in EGFR-mutated non-small cell lung cancer in Taiwan
Authors: C-C. Lin, P-L. Su, Y-T. Chou, C-Y. Lin, C-E. Wu, C-T. Yang, J.W-C. Chang
Journal: Journal of Thoracic Oncology (2023)
156P Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study
Authors: O.J. Juan Vidal, M.E. Gas Lopez, C. López Gómez, A. Loras Monfort, J.L. Valles Pardo, S. Palanca Suela, N. Mancheño Franch, E. Ansotegui, V. Calvo Medina, C. Muñoz Nuñez, F.J. Celada Alvarez, B. Martínez Sanchís, S. Marset García, J. Castejón Esteban, C. Cano Cerviño, J. Medina Alvarez, G. Garcia Rubia, A. Callejo Mellen, B. Valdivieso Martínez
Journal: Journal of Thoracic Oncology (2023)
18P Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): An update of the phase II, prospective study
Authors: J.Y. Chen, H. Zhang, B.Y. Wang, J.M. Wen, X.Y. Xu, H.T. Li, M. Fan
Journal: Journal of Thoracic Oncology (2023)
29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
Authors: S-G. Wu, Y-L. Huang, C-C. Ho, W-Y. Liao, T-H. Tsai, J.C-H. Yang, J-Y. Shih
Journal: Journal of Thoracic Oncology (2023)
140P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials, with focus on NSCLC
Authors: A. Mavrikios, C. Baldini, Y. Loriot, S. Ponce Aix, S. Champiat, F-X. Danlos, C. Quevrin, A. Gazzah, R. Bahleda, E. Deutsch, A. Levy
Journal: Journal of Thoracic Oncology (2023)
62P Predictive value of combined positive score (CPS) and tumor proportion score (TPS) for immunotherapy response in advanced non-small cell lung cancer (NSCLC)
Authors: E.B. Ulas, S. Hashemi, I. Houda, A. Kaynak, J. Veltman, M. Fransen, T. Radonic, I. Bahce
Journal: Journal of Thoracic Oncology (2023)
Split dCas12a activator for lncRNA H19 activation to enhance BMSC differentiation and promote calvarial bone healing
Authors: Nuong Thi Kieu Nguyen, Yi Tu, Hsiang-Sheng Lee, Vu Anh Truong, Yi-Hao Chang, Nam Ngoc Pham, Chin-Wei Chang, Ya-Hui Lin, Po-Liang Lai, Pin-Hsin Chen, Yelena V. Parfyonova, Mikhail Menshikov, Yu-Han Chang, Yu-Chen Hu
Journal: Biomaterials (2023)
42P Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042
Authors: Y-L. Wu, L. Zhang, Y. Fan, J. Zhou, L. Zhang, Q. Zhou, W. Li, C. Hu, G. Chen, X. Zhang, C. Zhou, C.G. Arenas, Z. Chen, W.C. Yu, T.S.K. Mok
Journal: Journal of Thoracic Oncology (2023)
130TiP Adjuvant osimertinib in patients with completely resected, stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations: A phase II, open-label, single arm, multicenter, exploratory study
Authors: C. Liu, J. Mei, F. Lin, Y. Lin, Y. Chen, L. Liu
Journal: Journal of Thoracic Oncology (2023)
37P Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis
Authors: J. Hu, X. Tang, R. Guo, Y. Wang, H. Shen, H. Wang, Y. Yao, X. Cai, Z. Yu, G. Dong, F. Liang, J. Cao, L. Zeng, M. Su, W. Kong, L. Liu, W. Huang, C. Cai, Y. Xie, W. Mao
Journal: Journal of Thoracic Oncology (2023)
40P Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
Authors: F. Opdam, J. Heymach, M. Barve, H-Y. Tu, Y-L. Wu, N.J. Gibson, B. Sadrolhefazi, J. Serra, K. Yoh, N. Yamamoto
Journal: Journal of Thoracic Oncology (2023)
210P Expression of cancer stem cell markers SOX-2 and OCT-4 and their regulation by nicotine in non-small cell lung carcinoma
Authors: J. Pazhani, V.P. Veeraraghavan, S. Jayaraman, M. El-Sherbiny, A.M. Ali Hakami, A. Mousaed Almotairi, H.A. Ebrahim
Journal: Journal of Thoracic Oncology (2023)
203P MET gene copy number heterogeneity in non-small cell lung cancer patients resistant to EGFR-TKIs
Authors: Q. Bai, Y. Chen, X. Xiao, H. Chang, B. Xin, L. Jia, J. Li, Z. Wang, C. Yu, H. Xiong, X. Zhou
Journal: Journal of Thoracic Oncology (2023)
198TiP Immuno-PET in predicting immune checkpoint inhibitor response in non-small cell lung cancer
Authors: S.G. Silva, D. Amorim, S. Feijó, F.J. Barata, A.M. Figueiredo, I. Hrynchak, M. Silva, A.P. Moreira, A. Abrunhosa, C. Cordeiro
Journal: Journal of Thoracic Oncology (2023)
43P Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
Authors: S. Ren, X. Wang, B. Han, Y. Pan, J. Zhao, Y. Cheng, S. Hu, T. Liu, Y. Li, Y. Cheng, J. Feng, S. Yi, S. Gu, S. Gao, Y. Luo, Y. Liu, C. Liu, H. Duan, C. Zhou, J. Fan
Journal: Journal of Thoracic Oncology (2023)
216P Differences in immune checkpoint inhibitor (ICI) approvals made by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for thoracic malignancies
Authors: N. Rizwan, D. Pottinger, R. Singh, K. Jatwani, A. Khosla, D.T. Michaeli, T. Michaeli, J. Warner, M.P. Lythgoe, A.R. Khaki, A. Desai
Journal: Journal of Thoracic Oncology (2023)
23P Impact of PDL1 expression on outcomes of patients with EGFR mutant NSCLC treated with EGFR TKIs: First results of the POET study
Authors: L. Belluomini, M.G. Ferrara, M. Sposito, A. Vitale, J. Insolda, E. Vita, D. Giannarelli, A. Stefani, M. Milella, E. Bria, S. Pilotto
Journal: Journal of Thoracic Oncology (2023)
14MO Updated efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC)
Authors: W. Li, N. Yang, K. Li, H. Fan, Q. Yu, H. Wu, Y. Wang, X. Meng, J. Wu, Z. Wang, Y. Liu, X. Wang, X. Qin, K. Lu, W. Zhuang, S. He, P.A. Janne, T. Seto, S-H.I. Ou, C. Zhou
Journal: Journal of Thoracic Oncology (2023)
60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
Authors: J. Neal, N. Pavlakis, S-W. Kim, Y. Goto, S.M. Lim, G. Mountzios, E. Fountzilas, A. Mochalova, D.C.C. Christoph, A. Bearz, X. Quantin, R. Palmero, V. Antic, E. Chun, T. Rao Edubilli, Y-C. Lin, M. Huseni, C. Scheffold, P. Vervaet, T. Newsom-Davis
Journal: Journal of Thoracic Oncology (2023)
174TiP PRIMALung (EORTC-1901): Prophylactic cerebral irradiation or active brain magnetic resonance imaging surveillance in small cell lung cancer patients
Authors: A. Lew, T. Berghmans, N. Andratschke, C. Dempsey, L. Flackett, G. Leonetti, M. Koller, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2023)
53P Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Authors: J. Perea, E. Gómez, C. Escrivá, A.V. Pellicer, P. Llor Rodriguez, J. Iranzo, O.J. Juan Vidal, J. García Sanchez, G. Suay Montagud, A. Ferrero Míco, I. Linares Diaz, N. Gómez Sepúlveda, E. Soria Hernández, J. Esteve Gallego, C. Carrasco, P. Capdevila Gaudens
Journal: Journal of Thoracic Oncology (2023)
66P Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
Authors: L. Zullo, E. Cella, F. Paoloni, M. Gualtieri, G. Barletta, D. Favero, F. Parisi, C. Dellepiane, G. Rossi, E. Bennicelli, L. Zinoli, L. Cantini, F. Pecci, L. Del Mastro, R. Berardi, C. Genova
Journal: Journal of Thoracic Oncology (2023)
11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors
Authors: M. Majem, M.D. Forster, M.G. Krebs, J. Peguero, T.D. Clay, E. Felip, W. Iams, P. Roxburgh, B. Doger de Spéville, P. Bajaj, C. Mueller, F. Triebel
Journal: Journal of Thoracic Oncology (2023)
102P A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a feasible prehabilitation program before lung cancer surgery
Authors: M. Voorn, M. Janssen-Heijnen, B. Bongers, C. Schröder, V.E.M. van Kampen-van den Boogaart, G. Bootsma, E.M.W. Bastiaansen
Journal: Journal of Thoracic Oncology (2023)
Abstract 2510: Culprit Lesion Remodeling Affects Long-Term Clinical Outcome in Patients with Acute Coronary Syndrome: A Prospective, Multicenter Three-Vessel Intravascular Ultrasound Study
Authors: Hiroyuki Okura, Haruyuki Taguchi, Yoshio Kobayashi, Satoru Sumitsuji, Mitsuyasu Terashima, Toru Kataoka, Motomaru Masutani, Mitsumasa Ohyanagi, Kenei Shimada, Yuji Yasuga, Yoshihiro Takeda, Yoshitaka Ohashi, Kojiro Awano, Kenichi Fujii, Gary S Mintz
Journal: Circulation (2008)

Single center studies have shown that plaque rupture and positive remodeling are prognostic predictors of acute coronary syndrome (ACS). A total of 119 patients with first ACS events were enrolled in a multicenter, prospective, 3-vessel intravascular ultrasound (IVUS) registry. Pre-intervention IVUS imaging was performed in 98 patients. Remodeling index was defined as lesion site external elastic membrane cross sectional area (EEM CSA) divided by the proximal reference. Arterial remodeling was defined as either positive (PR; remodeling index &gt;1.05) or intermediate/negative (IR/NR; remodeling index &lt;1.05). Plaque rupture was a cavity that communicated with the lumen with an overlying residual fibrous cap fragment. Major adverse cardiac events (MACE) were death, myocardial infarction (MI), and target lesion revascularization (TLR). During follow-up (mean 3 years), 20 TLR events and 5 deaths were documented; but recurrent MI was not observed. Patients with PR had significantly lower MACE-free survival than patients with IR/NR (Log rank, p=0.03). Similarly, patients with plaque rupture showed a non-significant trend toward lower MACE-free survival (Log rank, p=0.13). By multivariate logistic regression analysis, culprit lesion PR was the only independent predictor of follow-up MACE. Culprit lesion remodeling is a strong predictor of long-term clinical outcome in patients with ACS.